Zenas BioPharma (ZBIO)

• Market cap: $1.15B
• 1 day: 6.98%
• 5 days: 9.1%
• 1 month: -45.02%
• 3 months: -28.88%
• 6 months: 30.52%
• Year to date: -37.77%
• 1 year: 233.9%
• 5 years: 18.29%
• 10 years: 18.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130